Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluticasone Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 14/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | AR | P10275 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.78 |
| ▸ | CNR1 | P21554 | 1/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluticasone Propionate SCHEMBL14343427 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL15325049 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL15944858 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL4111260 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL13993454 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL191134 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL14339613 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL5482829 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL191133 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 | |
| Fluticasone Propionate SCHEMBL13602403 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 40163 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099512-A1 | MEDICAMENT DISPENSER DEVICE | PORTAL MEDICAL LIMITED (GB) | 2026-05-15 | — | — | WO | claimed |
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739295-A1 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-05-13 | — | — | EP | claimed |
| EP-4739294-A1 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-05-13 | — | — | EP | claimed |
| CN-117088932-B | Method for treating fluticasone propionate mother liquor | 黄冈人福药业有限责任公司 | 2026-05-12 | — | — | CN | claimed |
| US-12622872-B2 | Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions | NICOX OPHTHALMICS, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20260124153-A1 | METAL OXIDE ENCAPSULATED DRUG COMPOSITIONS AND METHODS OF PREPARING THE SAME | APPLIED MATERIALS INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12616803-B2 | Apparatus for dispensing inhalant medicament | METOPI PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-12616654-B2 | Stainless steel can for pressurised metered dose inhalers | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-05-05 | — | — | US | claimed |
| EP-0534731-A1 | Pressurised aerosol compositions | FISONS plc (GB) | 1993-03-31 | — | — | EP | claimed |
| EP-0278174-B1 | USE OF FLUTICASONE PROPIONATE IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF BOWEL DISEASES | GLAXO GROUP LIMITED (GB) | 1993-03-10 | — | — | EP | claimed |
| WO-1992018133-A1 | METHOD OF TREATMENT USING STEROID MOUTHWASH | EISEN DRORE (US) | 1992-10-29 | — | — | WO | claimed |
| WO-1992014472-A1 | COMPOSITIONS FOR TOPICAL ADMINISTRATION CONTAINING FLUTICASONE PROPIONATE AND OXICONAZOLE OR ITS SALTS | GLAXO GROUP LIMITED (GB) | 1992-09-03 | — | — | WO | claimed |
| US-5126123-A | Soluble surfactant stabilizer | GLAXO, INC. (US) | 1992-06-30 | — | — | US | claimed |
| WO-1992008447-A1 | AEROSOL CONTAINING MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 1992-05-29 | — | — | WO | claimed |
| WO-1992000107-A1 | AEROSOL DRUG FORMULATIONS | GLAXO INC. (US) | 1992-01-09 | — | — | WO | claimed |
| EP-0416951-A1 | Medicaments comprising salmeterol and fluticason | GLAXO GROUP LIMITED (GB) | 1991-03-13 | — | — | EP | claimed |
| US-4985418-A | STEROID FOR TREATING BOWEL DISEASE | GLAXO GROUP LIMITED (GB) | 1991-01-15 | — | — | US | claimed |
| EP-0278174-A2 | Use of fluticasone propionate in the preparation of a pharmaceutical composition for the treatment of bowel diseases | GLAXO GROUP LIMITED (GB) | 1988-08-17 | — | — | EP | claimed |